|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-3-13
|
|
pubmed:abstractText |
The efficacy and tolerability of the phosphate binder, lanthanum carbonate, have been evaluated in long-term comparative studies and subsequent open-label extensions. Animal studies show that lanthanum has a very low bioavailability and absorbed lanthanum is primarily excreted in bile. A specified subset of data from four Phase III clinical trials and subsequent extension studies is presented, in order to assess the effects of lanthanum carbonate on the liver.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0301-0430
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
286-95
|
|
pubmed:meshHeading |
pubmed-meshheading:19281739-Alanine Transaminase,
pubmed-meshheading:19281739-Alkaline Phosphatase,
pubmed-meshheading:19281739-Aspartate Aminotransferases,
pubmed-meshheading:19281739-Disease Progression,
pubmed-meshheading:19281739-Humans,
pubmed-meshheading:19281739-Kidney Failure, Chronic,
pubmed-meshheading:19281739-Lanthanum,
pubmed-meshheading:19281739-Liver,
pubmed-meshheading:19281739-Liver Function Tests,
pubmed-meshheading:19281739-Renal Dialysis,
pubmed-meshheading:19281739-gamma-Glutamyltransferase
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
|
|
pubmed:affiliation |
Manchester Royal Infirmary, Manchester, UK. alastair.hutchison@cmmc.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
